TuisORMP • NASDAQ
add
Oramed Pharmaceuticals, Inc.
Vorige sluiting
$2,39
Dagwisseling
$2,32 - $2,38
Jaarwisseling
$2,00 - $3,67
Markkapitalisasie
94,73 m USD
Gemiddelde volume
198,00 k
P/V-verhouding
23,53
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | — | — |
Bedryfskoste | 3,09 m | 6,77% |
Netto inkomste | -19,62 m | -508,91% |
Netto winsgrens | — | — |
Wins per aandeel | -0,48 | -500,00% |
EBITDA | -3,04 m | -6,97% |
Effektiewe belastingkoers | -6,12% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 142,30 m | -18,70% |
Totale bates | 165,08 m | -28,50% |
Totale aanspreeklikheid | 9,56 m | -88,44% |
Totale ekwiteit | 155,52 m | — |
Uitstaande aandele | 40,31 m | — |
Prys om te bespreek | 0,61 | — |
Opbrengs op bates | -4,42% | — |
Opbrengs op kapitaal | -4,64% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -19,62 m | -508,91% |
Kontant van bedrywe | -7,10 m | -923,20% |
Kontant van beleggings | -34,26 m | 54,39% |
Kontant van finansiering | -1,29 m | -101,73% |
Netto kontantverandering | -42,65 m | -3 183,22% |
Beskikbare kontantvloei | -277,62 k | 40,85% |
Meer oor
Oramed Pharmaceuticals Inc., is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange. Wikipedia
HUB
Gestig
2006
Webwerf
Werknemers
15
